Your browser doesn't support javascript.
loading
Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition.
Yan, Liang; Tu, Bo; Yao, Jun; Gong, Jing; Carugo, Alessandro; Bristow, Christopher A; Wang, Qiuyun; Zhu, Cihui; Dai, Bingbing; Kang, Ya'an; Han, Leng; Feng, Ningping; Jin, Yanqing; Fleming, Jason; Heffernan, Timothy P; Yao, Wantong; Ying, Haoqiang.
Afiliação
  • Yan L; Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tu B; Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yao J; Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gong J; Department of Biochemistry and Molecular Biology, UTHealth Medical School, Houston, Texas.
  • Carugo A; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bristow CA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang Q; Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zhu C; Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dai B; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kang Y; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Han L; Department of Biochemistry and Molecular Biology, UTHealth Medical School, Houston, Texas.
  • Feng N; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jin Y; Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fleming J; Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Heffernan TP; Division of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Yao W; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION), The University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ying H; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. hying@mdanderson.org wyao22@mdanderson.org.
Cancer Res ; 81(15): 4054-4065, 2021 08 01.
Article em En | MEDLINE | ID: mdl-34117030
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Carcinoma Ductal Pancreático / Inibidores de Proteínas Quinases / Glucose Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Adenocarcinoma / Carcinoma Ductal Pancreático / Inibidores de Proteínas Quinases / Glucose Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article